Business News Agency August 24th In the first half of 2010, China's Western medicine products have risen in volume and price, and imports have risen in price. It is estimated that China's total import and export of Western medicine products will maintain an increase of more than 25% for the whole year, but the policy will be the second half of the year. Uncertainties in the area are worth noting
Western medicine products are the main products for the import and export of Chinese medicine and health products, and the import and export volume accounts for 62% of the total import and export volume of medical insurance products. In the first half of 2010, the total value of imports and exports of western medicine products in China was US$17.645 billion, a year-on-year increase of 29.87%. The increase in import and export volume was 28.81%, which reflected that domestic and international consumption of Western medicine products maintained a good growth momentum; however, the average price only increased by 0.82% year-on-year, reflecting that the market competition is still fierce and the impact of the financial crisis has not been eliminated. Among the import and export volume, the export volume accounted for 66.78%, the import volume accounted for 33.22%, and the trade surplus was 5.921 billion U.S. dollars.
A Export volume and price rise in the market continued to improve
In the first half of 2010, Chinaâ€™s western medicine exports totaled US$11.783 billion, an increase of 33.9% year-on-year.
Overall, exports of western medicine products in the first half of the year have the following characteristics:
In the first half of the Western medicine market, the volume of raw materials and biochemicals rose, and the volume of Western medicine rose. From the perspective of export volume, biochemical drugs increased the most, as high as 65%, Western medicine and raw material drugs also increased by more than 30%. The growth of biochemical drugs exports is mainly reflected in the sharp increase in export prices, while Western medicines and APIs are mainly reflected in the growth of export volume. The large increase in export volume reflects the steady increase in the international demand for western medicine products. In particular, last yearâ€™s export volume has not declined due to the financial crisis. The export volume has increased significantly on the high base of last year, which is even more significant for our products. Good competitiveness and sustainable development potential of the international pharmaceutical market.
The mainstream market is stable and developed countries are
In the first half of the year, my Western medicine products were exported to 184 countries and regions. Asia, Europe and North America remain the major markets for my exports, with a share of 87.34%. My export growth to these three major markets exceeded 30%, which was 34.06% in Asia, 35.26% in Europe, and 32.79% in North America. Compared with 2009, the proportion of exports in the three major markets decreased slightly by 0.12% in Asia, slightly increased by 0.34% in North America, and increased by 0.85% in Europe. It can be seen that the export mainstream market of western medicine products is stable. In the first half of the year, the top 10 destinations for western medicines exports were the United States, India, Germany, Japan, South Korea, the Netherlands, Italy, Brazil, France, and Spain. The pattern of major exports of Western medicine products to developed countries has not changed. Among the top 10 export destination countries, 90% of the export volume has increased significantly, and the export volume to Brazil has increased by 74.56%. Only France has dropped by 9%. The average price of exports rose by half, and the average price of French exports rose the most, reaching 101%; the average price of Spanish exports fell the most, at 16.37%. This shows that the pharmaceutical market in developed countries is recovering quickly, but the low prices triggered by the financial crisis will continue.
Commodities soar, low-price competition intensifies
In the first half of the year, I exported 280 kinds of Western medicine products. According to the top 20 export brands, the export volume of 19 products increased, the 50% varieties rose more than 30%, and the export volume of other amino acids increased more than 80%, reflecting the strong growth in the export volume of Western medicine bulk products. The international market share is still growing steadily. However, from the perspective of export prices, the average price of eight kinds of products fell in the top 20 products, and the decline in the prices of three kinds of vitamin C and other lactone products exceeded 15%, reflecting that the export prices of western medicine products were not optimistic. The market maintenance and growth of products are realized at the expense of prices. The fierce price competition has both the pressure of international competitors and the result of domestic excess production capacity. It is difficult to make big changes in the short term.
Increased number of export companies, leader in manufacturing
In the first half of the year, there were 7,555 exporters of western medicine products with a record of performance, an increase of 8.63% year-on-year, which reflected the activeness of the western medicine market. Judging from the top 20 enterprises in terms of export value, 17 companies are manufacturing enterprises and only 3 foreign trade companies, reflecting that production companies have certain product and price advantages in the export of western medicine products, and lack of industrial support for foreign trade enterprises in production. Enterprises are at a disadvantage in export competition.
The export volume of the top 20 enterprises accounted for only 17.53% of the total exports of western medicine products, indicating that the concentration of western medicine export enterprises in China is not high. Among the top 20 companies, 80% of their exports have increased year-on-year, 30% have increased by more than 100%, and Weifang Yingxuan Industrial Co., Ltd. and North China Pharmaceutical Co., Ltd. have experienced an explosive growth in export volume, with an increase of 7458% respectively. And 2860%, which reflects the competitiveness of the industry's leading companies still have a clear advantage; but the average price of exports showed a half-trend, in which the average export price of heparin production enterprises doubled, but vitamin C companies generally fell 20 Above +%, the market changes in bulk products have led to significant differentiation in the performance of leading companies.
Private three- funded dance, outstanding coastal provinces
In the first half of the year, private enterprises and foreign-funded enterprises accounted for 38.65% and 31.4% of the total export enterprises, which was basically equal. The proportion of state-owned enterprises accounted for 23.81%, followed closely. However, the increase in the export prices of state-owned enterprises in the first half of the year was all above 10%. Private enterprises also rose in volume and price, and the volume rose mainly; only the export volume of foreign-funded enterprises rose by 45%, and the average price dropped by 10%. This shows that the price competition in developed countries' pharmaceutical markets is even fiercer.
From the perspective of the export situation of domestic provinces, the export of western medicine products is mainly concentrated in the coastal areas. Jiangsu, Zhejiang, Shandong, Shanghai and Hebei ranked first in the top 5 exports of western medicine products, and the proportion of exports of 5 provinces and cities was as high as 69%. Among them, the proportions of Jiangsu and Zhejiang reached 22.4% and 18.29% respectively. This shows that the concentration of western medicine products in China is relatively high, and the development of industrial clusters is obvious.
B. Increase in import price and decrease in price of finished medicine
In the first half of 2010, China imported 5.862 billion US dollars worth of Western medicine products, an increase of 22.45% year-on-year.
In the first half of the year, the overall import volume of western medicine products showed a trend of declining prices. The import volume increased by 25.78% and the average import price dropped by 2.64%. However, in the three major categories of imported products, the imports of APIs and biochemicals all showed a rise in volume and price, but the average import price of Western medicine dropped by 10.33% as a result of the proportion of 38.18%, dragging down the overall average import prices. The fall in the average price of imported western medicines, which is not only caused by the continuing low prices of raw material medicines, caused the reduction of the production cost of western medicines, but also increased the substitution ability of domestic generic drugs.
Europe shrinks and Asia and North America increase
Europe, Asia and North America are the major market sources for imports of Western medicine products. In the first half of the year, the import of the three largest markets maintained a high level of concentration of nearly 97%. Overall, they remained stable, but the subdivision pattern changed slightly. The largest source market was. The proportion of Europe dropped from 61.92% in 2009 to 59.06%, and it has shrunk significantly. The share of the Asian market increased by 2 percentage points to 25%, and both import volume and import prices rose sharply. Although the proportion of North American market has also increased by 1 percentage point, the import price has dropped by 18%, mainly due to the decline in the import price of Western Medicine. The United States, Germany, Japan, Switzerland, France, Italy, Belgium, Ireland, Sweden, and India are the top 10 source countries for imports of Western medicine products. The proportion of imports from them is 65%, and the United States and Germany share more than 12%. Among them, imports from these nine countries have increased, with the largest increase being Italy, with an increase of more than 50%. The only decline is in Ireland; but the average import price has fallen by more than half, Germany has fallen the most. Nearly 30%. The average import price from Italy stands out, rising by as much as 80.5%. The reason for the year-on-year decline in the average price of imported Western medicine products from developed countries was that the high-end product prices did not drop significantly due to the financial crisis last year, which was higher than the base year-on-year. Second, the prices of raw materials for high-end products decreased, which drove down the prices of deep-processed products.
Preparation-led, prices rose more or less
In the first half of the year, I imported a total of 255 kinds of western medicine products. Among the top 10 varieties of imported products, 60% are Western medicine or biochemical preparations, and the import value accounts for nearly 40% of the total imports of western medicine products. This is in stark contrast to the fact that all of my leading export products are APIs. From the point of view of the average import price, except for the average import price of hormone preparations, which rose by 17%, the average import prices of other preparations dropped by more than 10%.
Multinational drug companies as the main force, logistics industry rush
In the first half of the year, a total of 1,000 companies had the import performance of western medicine products, and the top 20 of the import volume were mostly foreign-funded enterprises. The foreign-funded enterprises' imports accounted for 58.34% of the total imports, of which foreign-owned foreign-funded enterprises dominated by transnational pharmaceutical companies accounted for nearly 39% of the total. They have become the absolute main force for the import of western medicine products in China.
There is little difference between the import capacity of private enterprises and state-owned enterprises, each accounting for about 20%. It is worth noting that the No. 1 import ranking is Yongyu (Shanghai) Pharmaceutical Logistics Operations Co., Ltd. and Shanghai Guoyao Waigaoqiao Pharmaceutical Co., Ltd. also ranks No. 3 in the first half of the import value. The status of trading companies in import is also More and more prominent.
C. Excessive production capacity of large varieties deserves vigilance
In the second half of the year, the export prices of western medicine products in China formed downward pressure, and the overall price trend was not optimistic.
From the situation of import and export of western medicine products in the first half of 2010, the international western medicine product production and consumption market maintained a steady growth momentum, and the western medicine products in China also showed a trend of import and export booming, but the low price situation was difficult in the short term. There is a big change.
The author believes that after experiencing the financial crisis, the quality and reputation of western medicine products in China have been recognized by the international market. The scale advantages of some products will not be challenged in the short term, and the international market share is expected to remain stable and will increase. This will ensure that the export volume of western medicine products in China will maintain its growth momentum in the second half of the year. However, the overcapacity of bulk varieties and the low prices of western medicine products in the international market will cause downward pressure on the export prices of western medicine products in the second half of the year. The overall price trend is not optimistic.
The import of western medicine products in China is relatively stable, and will basically continue the trend in the first half of the year. The quantity will increase and the price will decline. It is expected that China's imports and exports of western medicine products will maintain a growth of more than 25% for the whole year, and the increase in exports will be higher than the increase in imports. It is worth noting that the policy uncertainties in the second half of the year are also relatively high. The changing trend of the RMB exchange rate and export tax rebates will reduce the price competitiveness of Chinese products. The increase in environmental pressure and the rise in raw material prices will squeeze the company's profit margins. Even affecting the company's production and operating capabilities, serious overcapacity of certain varieties of production will inevitably cause price fluctuations in the international market, which will have a real impact on the trend of imports and exports of Western medicine products in China, increasing the uncertainty in the second half of the trend.
Medical Compressed Air Plant ,Hospital Gas System ,Hospital Gas Pipeline System ,Medical Air Compressor
Hunan Eter Medical Co., Ltd. , https://www.eter-tech.com